As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) has demonstrated real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a few companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.
Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.
Read more about how Tekmira is developing its own RNAi product candidates. In addition, since its inception, Tekmira has fostered collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Halo-Bio RNAi Therapeutics, Inc., Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company, and the United States Government's Transformational Medical Technologies (TMT) Program. Read more about Tekmira's current partnerships.